SUN PHARMACEUTICAL IND L (SUNPHARMA)
companyActive threads
Regulator orders Sun Pharma to halt eye-care drug production at Assam plant
India orders Sun Pharma to halt eye-care drug production at plant after quality lapses: Report - Published OnOct 30, 2026 | 16:54 IST - Last Updated OnOct 30, 2026 | 16:54 IST Indian regulators ordered Sun Pharmaceutical Industries to halt ophthalmic drug production at its Assam facility after finding quality management system failure.
Sun Pharma Q2 profit drops 36% to Rs 1,989 crore on acquisition charges
Sun Pharma reported a 36% year-on-year fall in Q2 profit to Rs 1,989 crore, dragged down by one-time acquisition-related charges. US sales met expectations while other operating parameters beat estimates, with coverage framing the quarter as a mixed but largely resilient performance.
Sun Pharma shares rally as USFDA approves ILUMYA for arthritis
Sun Pharma shares extend 4-day rally after USFDA approval for ILUMYA in arthritis patients - Published OnOct 30, 2026 | 10:14 IST - Last Updated OnOct 30, 2026 | 10:14 IST Expanding from skin treatments into joint care, the drug's new regulatory clearance unlocks a massive patient market previously limited by self-administration hurdles. Clinical trials confirmed rapid symptom relief, reinforcing the therapy's commercial pipeline.
Sun Pharma to raise ₹10,000cr via bonds for Organon deal
Sun Pharmaceutical Industries plans to raise ₹10,000 crore through two tranches of rupee-denominated bonds. The funds will help refinance bridge loans taken for the Organon acquisition valued at $11.75 billion. The first tranche will amount to ₹7,000 crore with a coupon rate of 8.20%.
Sun Pharma's innovative portfolio and Organon deal drive growth outlook
Expanding innovative portfolio may drive gains for Sun Pharma stock Lerodalcibep licensing deal, growth in the US portfolio and tariff relief offer triggers, while the proposed Organon acquisition could broaden its global reach Listen to This Article The outlook for Sun Pharma is expected to improve on the back of multiple positive triggers. These include scaling up of its US portfolio, expanding innovative portfolio and tariff deal/specialty drug tariff waiver.
Intelligence feed· 2 articles in 1440m
Street stays bullish on Sun Pharma despite mixed Q2, earnings downgrades
New: Street stays bullish on Sun Pharma despite mixed Q2, earnings downgrades
Sun Pharma Share Price Live Updates: Sun Pharma's Recent Performance - The Economic Times
Story first reported.